These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 36060249)

  • 1. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.
    Ribeiro R; Carvalho MJ; Goncalves J; Moreira JN
    Front Mol Biosci; 2022; 9():903065. PubMed ID: 36060249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research advances and new challenges in overcoming triple-negative breast cancer.
    Zong Y; Pegram M
    Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
    Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
    Front Oncol; 2022; 12():779786. PubMed ID: 35646659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer.
    Ensenyat-Mendez M; Orozco JIJ; Llinàs-Arias P; Íñiguez-Muñoz S; Baker JL; Salomon MP; Martí M; DiNome ML; Cortés J; Marzese DM
    Commun Med (Lond); 2023 Jul; 3(1):93. PubMed ID: 37430006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
    Dixon-Douglas J; Loi S
    Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice.
    Carlino F; Diana A; Piccolo A; Ventriglia A; Bruno V; De Santo I; Letizia O; De Vita F; Daniele B; Ciardiello F; Orditura M
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches.
    Geurts V; Kok M
    Curr Treat Options Oncol; 2023 Jun; 24(6):628-643. PubMed ID: 37079257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker.
    Qureshi S; Chan N; George M; Ganesan S; Toppmeyer D; Omene C
    Biomark Insights; 2022; 17():11772719221078774. PubMed ID: 35221668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Present and Future of Immunotherapy for Triple-Negative Breast Cancer.
    Sriramulu S; Thoidingjam S; Speers C; Nyati S
    Cancers (Basel); 2024 Sep; 16(19):. PubMed ID: 39409871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive.
    Nandini D; Jennifer A; Pradip D
    Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34065837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
    Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer.
    Jacobs F; Agostinetto E; Miggiano C; De Sanctis R; Zambelli A; Santoro A
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
    Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
    Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress and challenges of immunotherapy in triple-negative breast cancer.
    Zhu Y; Zhu X; Tang C; Guan X; Zhang W
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical promise of immunotherapy in triple-negative breast cancer.
    Vikas P; Borcherding N; Zhang W
    Cancer Manag Res; 2018; 10():6823-6833. PubMed ID: 30573992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.